Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer.
Kolberg HC, Lövey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Hoffmann O, Bulsara M, Vaidya J, Liedtke C. Kolberg HC, et al. Among authors: hoffmann o. Breast Care (Basel). 2017 Oct;12(5):318-323. doi: 10.1159/000479424. Epub 2017 Sep 21. Breast Care (Basel). 2017. PMID: 29234252 Free PMC article.
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, Hein A, Häberle L, Jud SM, Lux MP, Janni W, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kümmel S, Martin B, Thomssen C, Graf H, Wolf C, Bayer CM, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb TF, Nabieva N, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Wallwiener D, Rack B, Fehm T, Rody A, Maass N, Beckmann MW, Fasching PA, Rauh C. Wunderle M, et al. Among authors: hoffmann o. Breast Cancer Res Treat. 2019 Apr;174(2):453-461. doi: 10.1007/s10549-018-05115-6. Epub 2019 Jan 2. Breast Cancer Res Treat. 2019. PMID: 30603996 Clinical Trial.
An Ultralow-Dose 1-Day Protocol With Activities Lower Than 20 MBq for the Detection of Sentinel Lymph Nodes in Breast Cancer-Experiences After 150 Cases.
Kolberg HC, Afsah S, Kuehn T, Winzer U, Akpolat-Basci L, Stephanou M, Wetzig S, Hoffmann O, Liedtke C. Kolberg HC, et al. Among authors: hoffmann o. Technol Cancer Res Treat. 2017 Dec;16(6):1079-1082. doi: 10.1177/1533034617728862. Epub 2017 Sep 6. Technol Cancer Res Treat. 2017. PMID: 28875761 Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb T, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA. Nabieva N, et al. Among authors: hoffmann o. Int J Cancer. 2019 Oct 15;145(8):2114-2121. doi: 10.1002/ijc.32294. Epub 2019 Apr 2. Int J Cancer. 2019. PMID: 30901076 Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T; DETECT study group. Müller V, et al. Among authors: hoffmann o. ESMO Open. 2021 Dec;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25. ESMO Open. 2021. PMID: 34839105 Free PMC article.
342 results